Back
Summit Therapeutics 10K Form
Sell
50
SMMT
Summit Therapeutics
Last Price:
20.25
Seasonality Move:
33.87%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2023-11-07 | 10Q | SMMT/Summit Therapeutics Quarterly |
2023-08-09 | 10Q | SMMT/Summit Therapeutics Quarterly |
2023-05-11 | 10Q | SMMT/Summit Therapeutics Quarterly |
2022-11-09 | 10Q | SMMT/Summit Therapeutics Quarterly |
2022-08-11 | 10Q | SMMT/Summit Therapeutics Quarterly |
2022-05-11 | 10Q | SMMT/Summit Therapeutics Quarterly |
Receive SMMT News And Ratings
See the #1 stock for the next 7 days that we like better than SMMT
SMMT Financial Statistics
Sales & Book Value
Annual Sales: | $705K |
---|---|
Cash Flow: | $-33.07M |
Price / Cash Flow: | 0 |
Annual Sales: | $0.27 |
Price / Book: | 75.16 |
Profitability
EPS (TTM): | -0.19000 |
---|---|
Net Income (TTM): | $-161.69M |
Gross Margin: | $760K |
Return on Equity: | 0% |
Return on Assets: | 0% |
Summit Therapeutics Earnings Forecast
Key Summit Therapeutics Financial Ratios
- The Gross Profit Margin over the past 15 years for SMMT is 102.29%.
- The Selling, General & Administrative Expenses for SMMT have been equal to 3,787.23% of Gross Profit Margin.
- The Interest Expense is -2.68% of Operating Income.
- Per Share Earnings over the last 19 years have been positive in 8 years.
Summit Therapeutics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | SMMT |
CUSIP: | 86627R |
Website: | smmttx.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 0 |
Quick Ratio: | 0 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
SMMT Technical Analysis vs Fundamental Analysis
Sell
50
Summit Therapeutics (SMMT)
is a Sell
Is Summit Therapeutics a Buy or a Sell?
-
Summit Therapeutics stock is rated a Sell
The current Summit Therapeutics [SMMT] share price is $19.95. The Score for SMMT is 50, which is 0% below its historic median score of 50, and infers higher risk than normal.